Company Overview

Evotec SE is a Germany-based drug discovery and development company operating in the biotechnology and pharmaceutical services industries. The company focuses on providing integrated solutions for the discovery, development, and manufacturing of drug candidates, working primarily through strategic partnerships with pharmaceutical companies, biotechnology firms, and academic institutions. Evotec’s business model is centered on research services, platform-based drug discovery, and participation in downstream value through milestones, royalties, and equity interests.

The company’s primary revenue drivers include research collaboration payments, discovery and development services, and milestone-based income from partnered drug programs. Evotec serves global pharmaceutical and biotechnology customers, with a strong emphasis on early-stage research, translational medicine, and precision medicine approaches. Founded in 1993 and initially focused on neurodegenerative diseases, Evotec has evolved through acquisitions and platform expansion into a broad drug discovery partner with capabilities spanning small molecules, biologics, cell therapies, and induced pluripotent stem cell (iPSC) technologies.

Business Operations

Evotec operates through multiple integrated business segments, primarily EVT Execute and EVT Innovate, which together cover fee-for-service research, long-term discovery alliances, and proprietary pipeline development. EVT Execute focuses on contract research and development services, generating revenue through customer-funded research projects and platform access. EVT Innovate emphasizes co-owned and proprietary research programs, where Evotec retains economic participation through milestones, royalties, and equity stakes.

The company conducts operations across both domestic and international markets, leveraging advanced discovery platforms in areas such as computational drug design, high-throughput screening, biologics engineering, and iPSC-based disease modeling. Evotec controls a network of specialized subsidiaries, including Evotec (Hamburg) GmbH, Evotec (UK) Ltd., and Evotec Red SAS, and maintains long-term strategic partnerships with major pharmaceutical companies including multi-year alliances in oncology, neuroscience, and metabolic diseases.

Strategic Position & Investments

Evotec’s strategic direction emphasizes long-term value creation through platform scalability, shared-risk partnerships, and selective investment in proprietary pipelines. Growth initiatives include expanding industrialized drug discovery platforms, strengthening biologics and cell therapy capabilities, and increasing participation in late preclinical and clinical-stage assets through co-development structures. The company has consistently reinvested in technology infrastructure to support automation, artificial intelligence, and data-driven drug discovery.

Major acquisitions have played a central role in Evotec’s expansion, including Just – Evotec Biologics, which significantly enhanced its biologics manufacturing and development capabilities, and Bayer’s drug discovery unit in Wuppertal, which broadened Evotec’s scientific footprint and long-term collaboration pipeline. The company is actively involved in emerging therapeutic areas such as precision medicine, rare diseases, and cell-based therapies, often through jointly owned portfolio companies and academic spin-outs.

Geographic Footprint

Evotec is headquartered in Hamburg, Germany, and maintains a substantial global presence across Europe, North America, and Asia-Pacific. Its European operations include major research sites in Germany, France, and the United Kingdom, serving as the backbone of its discovery and early development activities. In North America, the company operates significant facilities in the United States, particularly focused on biologics development and integrated drug discovery services.

The company’s international footprint supports a globally diversified customer base and enables collaboration with multinational pharmaceutical partners. Evotec’s geographic reach also facilitates access to regional innovation ecosystems, public-private research funding, and localized manufacturing and development capabilities, reinforcing its position as a global drug discovery partner.

Leadership & Governance

Evotec’s leadership team combines scientific, operational, and financial expertise, with a governance structure designed to support long-term partnerships and sustainable growth. The company emphasizes a collaborative leadership philosophy focused on innovation, disciplined capital allocation, and alignment with partners’ research priorities. Strategic vision centers on building an industrialized drug discovery platform capable of delivering repeatable scientific and financial outcomes.

Key executives include:

• Christian Wojczewski – Chief Executive Officer
• Enno Spillner – Chief Financial Officer
• Cord Dohrmann – Chief Scientific Officer
• Craig Johnstone – Chief Operating Officer
• Mario Polywka – Chief Strategy Officer

The management team operates under the oversight of a Supervisory Board consistent with German corporate governance standards, ensuring separation of management and supervisory functions and alignment with shareholder interests.